Avid Bioservices Inc (CDMO)

[freethemice]

I repeated the exercise for the first-line treatment arms of the 12 trials. There are a few interesting things to note.
One is that the mean MOS/PFS for these trials is 1.98, considerably less than the 2.84 for the second-line
treatment arms, and less noisy. Also, the Bavi first-line signal-seeking trial had a MOS/PFS = 2.03,
which is totally consistent with these, and had a MOS of 12.4 months, which is exactly the mean of
the two estimates given here for the randomized first-line MOS. This tells me the first-line NSCLC signal-seeking
trial is probably consistent with the randomized first-line trial.
It is also interesting that the mean of the two estimates given for the second-line MOS is 12.4, and agrees
with the mean estimate for the first-line MOS given here. That would be something if adding bavi to docetaxel
for second-line patients could extend survival as much as for first-line patients.